Use of Monte Carlo simulation to assess the pharmacodynamics of β-lactams against Pseudomonas aeruginosa infections in children: A report from the OPTAMA program

Clinical Therapeutics

Volumn 27, Issue 11, 2005, Pages 1820-1830

  Ellis, Jennifer M ^a   Kuti, Joseph L ^b   Nicolau, David P ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobial; Pediatric; Pharmacodynamic; Pseudomonas aeruginosa

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PEDIATRICS; PREDICTION; PROBABILITY; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; BETA-LACTAMS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA;

EID: 29144505355     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.11.007     Document Type: Article

References (42)

1. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System Pediatrics 103 1999 e39
2. Urrea M., Pons M., and Serra M. Prospective incidence study of nosocomial infections in a pediatric intensive care unit Pediatr Infect Dis J 22 2003 490 494
3. Wisplinghoff H., Seifert H., and Tallent S.M. Nosocomial bloodstream infections in pediatric patients in United States hospitals: Epidemiology, clinical features and susceptibilities Pediatr Infect Dis J 22 2003 686 691
4. Jones M.E., Karlowsky J.A., and Draghi D.C. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients Eur J Clin Microbiol Infect Dis 23 2004 445 455
5. Jones R.N., Biedenbach D.J., and Beach M.L. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): Report from the SENTRY Antimicrobial Surveillance Program Diagn Microbiol Infect Dis 46 2003 77 80
6. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 12
7. Tam V.H., McKinnon P.S., and Akins R.L. Pharmacodynamics of cefepime in patients with Gram-negative infections J Antimicrob Chemother 50 2002 425 428
8. Ambrose P.G., Grasela D.M., and Grasela T.H. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with communityacquired respiratory tract infections Antimicrob Agents Chemother 45 2001 2793 2797
9. Craig W.A., and Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media Pediatr Infect Dis J 15 1996 255 259
10. Drusano G.L. Prevention of resistance: A goal for dose selection for antimicrobial agents Clin Infect Dis 36 Suppl 1 2003 S42 S50
11. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002 Antimicrob Agents Chemother 48 2004 2464 2470
12. Kiffer C.R., Mendes C., Kuti J.L., and Nicolau D.P. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumanniiand Pseudomonas aeruginosa from the MYSTIC surveillance program: The OPTAMA Program, South America 2002 Diagn Microbiol Infect Dis 49 2004 109 116
13. Masterton R.G., Kuti J.L., Turner P.J., and Nicolau D.P. The OPTAMA programme: Utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe J Antimicrob Chemother 55 2005 71 77
14. Clinical and Laboratory Standards Institute Performance Standards for Anti-microbial Susceptibility Testing. Fifteenth Informational Supplement Document M100 S15 2005 CLSI Wayne, Pa
15. American Academy of Pediatrics Red Book: Report of the Committee on Infectious Diseases 26th ed. 2003 American Academy of Pediatrics Oak Grove Village, Ill
16. Nelson J.D. Bradley J.S. Nelson's Pocket Book of Pediatric Antimicrobial Therapy 14th ed. 2000 Lippincott Williams & Wilkins Philadelphia
17. Available at: Kuczmarski R.J., Ogden C.L., and Guo S.S. 2000 Growth charts for the United States: Methods and development Accessed January 16, 2004
18. Gura K.M. Intravenous drug administration guidelines for pediatric patients J Pediatr Pharm Pract 4 1999 80 106
19. Engelhard D., Shalit I., and Stutman H.R. Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients Pediatr Pharmacol (New York) 5 1986 273 279
20. Reed M.I.D., Yamashita T.S., and Krupp C.K. Pharmacokinetics of intravenously and intramuscularly ad ministered cefepime in infants and children Antimicrob Agents Chemother 41 1997 1783 1787
21. Blumer J.L., Reed M.D., and Kearns G.L. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children Antimicrob Agents Chemother 39 1995 1721 1725
22. Reed M.D., Goldfarb J., and Yamashita T.S. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children Antimicrob Agents Chemother 38 1994 2817 2826
23. Prokhorenko P.I., Strachunskii L.S., and Andreenkova E.G. Age-related characteristics of ceftazidime pharmacokinetics in children [in Russian] Antibiot Khimioter 37 1992 29 31
24. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid Infect Dis Clin North Am 17 2003 479 501
25. Bradley J.S., Dudley M.N., and Drusano G.L. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation Pediatr Infect Dis J 22 2003 982 995
26. Drusano G.L. Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug' Nat Rev Microbiol 2 2004 289 300
27. Mouton J.W., Dudley M.N., and Cars O. Standardization of pharmacokinetic/ pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update J Antimicrob Chemother 55 2005 601 607
28. Kuti J.L., Dandekar P.K., Nightingale C.H., and Nicolau D.P. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem J Clin Pharmacol 43 2003 1116 1123
29. Gibaldi M. Introduction to pharmacokinetics Gibaldi M. Biopharmaceutics and Clinical Pharma cokinetics 3rd ed. 1984 Lea & Febiger Philadelphia 1 16
30. Leibovici L., Shraga I., and Drucker M. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection J Intern Med 244 1998 379 386
31. de Man P., Verhoeven B.A., and Verbrugh H.A. An antibiotic policy to prevent emergence of resistant bacilli Lancet 355 2000 973 978
32. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients Chest 115 1999 462 474
33. Ariffin H., Navaratnam P., and Mohamed M. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia Int J Infect Dis 4 2000 21 25
34. Fleischhack G., Hartmann C., and Simon A. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer J Antimicrob Chemother 47 2001 841 853
35. Kutluk T., Kurne O., and Akyuz C. Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid to mours Pediatr Blood Cancer 42 2004 284 286
36. Bradley J.S., and Arrieta A. Empiric use of cefepime in the treatment of lower respiratory tract infections in children Pediatr Infect Dis J 20 2001 343 349
37. Hsu H.L., Lu C.Y., and Tseng H.Y. Empirical monotherapy with meropenem in serious bacterial infections in children J Microbiol Immunol Infect 34 2001 275 280
38. Safdar N., Handelsman J., and Maki D.G. Does combination antimicrobial therapy reduce mortality in gram negative bacteraemia? A metaanalysis Lancet Infect Dis 4 2004 519 527
39. Lodise T.P., McKinnon P.S., Swiderski L., and Rybak M.J. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia Clin Infect Dis 36 2003 1418 1423
40. Burgess D.S., and Nathisuwan S. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa Diagn Microbiol Infect Dis 44 2002 35 41
41. Drusano G.L., Preston S.L., and Hardalo C. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint Antimicrob Agents Chemother 45 2001 13 22
42. Ritschel W.A., and Kearns G.L. Handbook of Basic Pharmacokinetics- Including Clinical Applications 6th ed. 2004 American Pharmaceutical Association Washington, DC